Articles related to ADVERSE EVENTS

Adults with type 2 diabetes initiating GLP-1 receptor agonists experienced higher rates of nonscarring alopecia than matched users of SGLT-2 or DPP-4 inhibitors. The association persisted across multiple analyses, though absolute risk remained low.

Across 14 health-system specialty pharmacies, pharmacist interventions were associated with an estimated $3.6 million in avoided medication costs over six months. The analysis used a structured attribution method to assess the likelihood that individual interventions altered treatment trajectories.

A phase 3 trial in extensive-stage small cell lung cancer found that adding concurrent thoracic radiotherapy to chemoimmunotherapy did not improve survival outcomes and was associated with higher toxicity. Investigators reported more adverse events and treatment-related deaths, raising safety concerns about this combination strategy.

A retrospective analysis of FDA postmarketing reports identified textural changes, pigmentary alteration, and subcutaneous fat loss as the most frequently reported adverse events following radiofrequency microneedling, with most cases occurring on the face and submental area.

Cotrimoxazole was associated with nearly twice the adverse event rate of fluoroquinolones in a retrospective study of 228 hospitalized men aged 75 or older with urinary tract infections, with acute kidney injury onset occurring at a median of six days post-initiation.

Ipsen voluntarily withdrew tazemetostat in follicular lymphoma and epithelioid sarcoma after 18 of 318 SYMPHONY-1 participants developed hematologic second primary malignancies, including three deaths.